Clinical

Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.

The respiratory syncytial virus (RSV) vaccine shows strong immunogenicity and safety in immunocompromised adults, study finds.

Malnutrition significantly increases the 180-day hospital readmission rates among patients 65 years or older with chronic obstructive pulmonary disease (COPD), highlighting the importance of monitoring and improving their nutritional status.

Hepatitis B virus (HBV) is associated with an increased risk of cervical cancer but not ovarian or endometrial cancers.

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted with patients.

Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery.

Patients with symptoms of gastrointestinal (GI) problems and survivors of colon cancer were more likely to use oncology specialty care.

An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.

Patients with cardiometabolic diseases who follow an anti-inflammatory diet have better brain health and a lower risk of dementia.

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.

A series of portable respiratory function tests for patients with mild to moderate myasthenia gravis (MG) were found to be useful methods to diagnose previously unidentified at-risk cases for respiratory deterioration.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

The FDA has approved nemolizumab (Nemluvio; Galderma) to treat patients with prurigo nodularis based on successful phase III trials demonstrating significant reductions in itch and sleep disturbances.

A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.

Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering the specific needs and risks of each child.

The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found.

Medicare Advantage beneficiaries with chronic obstructive pulmonary disease (COPD) who were invited to enroll in a program that reduced inhaler costs and provided medication management had higher inhaler adherence; however, there was no significant impact on exacerbations or overall health care spending.

Reynold A. Panettieri Jr., MD, elaborates on the risks of lung damage resulting from exacerbations, with a focus on the role of type 2 inflammation in triggering these events.

A key opinion leader examines the etiology of asthma and potential risk factors for COPD development, emphasizing the role of environmental exposures.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

In this analysis, outcomes were investigated among 41 pediatric and young adult patients who had soft-tissue sarcoma and were aged 0 months to 22 years.

The involvement of 2 surgeons during cytoreductive debulking and bowel surgery in patients with epithelial ovarian cancer significantly reduces the rate of anastomotic leaks.

A high number of adverse events were reported in a late-stage trial conducted by Merck for treatment in lung cancer.

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.